Astellas Pharma will pay Dyno a license fee to use its engineered AAV capsid, as well as possible milestone payments and royalties.

Oricell Therapeutics on Thursday said it has raised $110 million in a pre-initial public offering financing round as it looks to break into international markets. The Shanghai-based company's lead ...

Through a six-month pilot program at Pacific Cancer Care, the firms are assessing if they can improve guidelines-backed ...

NEW YORK – Acurion has raised $4.3 million in seed funding to further establish its OncoGaze digital pathology platform's ability to detect biomarkers from cancer hematoxylin and eosin slides and ...

The firm also plans to file a clinical trial application for another RNA drug targeting the same liver protein by mid-2026.

The firm is clinically testing the dual inhibitor in breast, prostate, colorectal, and lung cancer patients, as Pfizer is also exploring a similar dual-target strategy.

Under the expanded collaboration, Gilead will use Tempus' platform to analyze more patient data for oncology drug development and clinical trial design.

The firm dosed the first person in a Phase I trial of ALZ-507 in healthy volunteers, which will inform dosing in subsequent Phase II trials.

Funded by the Cancer Grand Challenges initiative, the UK branch of the trial has already enrolled the first patient.

A study found that in about 10 percent of patients, WGS picked up on clinically actionable information other panels missed.

Preclinical testing has suggested that AIR-001 increases functional AAT protein levels and could address the lung and liver manifestations of the disease.